Skip to content

Clinical trials

Coronary Artery Disease trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Coronary Artery Disease Status: Unknown status Country / region: China Clear all

173 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20051
20087
20098
201010
20114
20128
20133
20148
201510
201613
201714
201820
201910
202010
202122
20228
202312
20244

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status173

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Beijing Anzhen Hospital13
China National Center for Cardiovascular Diseases12
Chinese Academy of Medical Sciences, Fuwai Hospital10
Shanghai Zhongshan Hospital10
The First Affiliated Hospital with Nanjing Medical University6
Xijing Hospital6
Nanjing Medical University5
Shanghai Jiao Tong University School of Medicine5
Chinese PLA General Hospital4
Lepu Medical Technology (Beijing) Co., Ltd.4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Coronary Artery Disease173
Coronary Disease8
Cardiovascular Diseases7
Myocardial Ischemia7
Diabetes Mellitus6
Coronary Stenosis5
Myocardial Infarction5
Acute Coronary Syndrome4
Angina, Stable4
Angina, Unstable3

Trials

Showing 1 to 25 of 173. Each trial links to its page on Pharma Observatory.

73 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.